A characteristic bacterial SERS marker for direct identification of Salmonella in real samples assisted by a high-performance SERS chip and a selective culture medium.

Article

Author: Yang, Jinmei ; Ge, Chaojie ; Hui, Qi ; Cao, Yanrong ; Shen, Siyuan ; Wang, Danyan ; Jin, Lei ; You, Guohui

Salmonella should be absent in pharmaceutical preparations and foods according to the regulations. However, up to now, rapid and convenient identification of Salmonella is still full of challenge. Herein, we reported a label-free surface-enhanced Raman scattering (SERS) method for direct identification of Salmonella spiked in drug samples based on a characteristic bacterial SERS marker assisted by a high-performance SERS chip and a selective culture medium. The SERS chip being fabricated through in situ growth of bimetallic Au-Ag nanocomposites on silicon wafer within 2 h, featured a high SERS activity (EF > 10⁷), good uniformity and batch-to-batch consistency (RSD < 10 %), and satisfactory chemical stability. The directly-visualized SERS marker at 1222 cm^-1 originated from bacterial metabolite hypoxanthine was robust and exclusive for discrimination of Salmonella with other bacterial species. Moreover, the method was successfully used for direct discrimination of Salmonella in mixed pathogens by using a selective culture medium, and could identify Salmonella contaminant at ∼1 CFU spiked level in a real sample (Wenxin granule, a botanical drug) after 12 h of enrichment. The combined results showed that developed SERS method is practical and reliable, and could be a promising alternative for rapid identification of Salmonella contamination in pharmaceutical and foods industries.

01 Nov 2022·Journal of Ethnopharmacology

Discovery of Q-markers of Wenxin Formula based on a Chinmedomics strategy

Article

Author: Sun, Hui ; Han, Ying ; Zhang, Ai-Hua ; Wang, Xi-Jun ; Ma, Wei-Tong ; Yan, Guang-Li ; Liu, Chang ; Wang, Zong-Wei

ETHNOPHARMACOLOGICAL RELEVANCEWenxin Formula (WXF) is a well-known prescription with a significant curative effect in the treatment of cardiac disease. However, the lack of quality control standards caused by unclear quality control components limits the development of new drugs.AIM OF THE STUDYThe aims of this research were to discover the effective materials and screen the quality markers of WXF through a chinmedomics strategy to aid in efficacy evaluation.MATERIAL AND METHODSThe therapeutic effect of WXF against myocardial ischaemia (MI) was evaluated by serum metabolic profiling combined with routine electrocardiography; analyses of the serum biochemical indices CK, CK-MB and α-HBDH; and histopathological tests involving TTC staining and HE staining. The raw data of serum samples were obtained by UPLC-HDMS, and multivariate statistical analysis was performed with Progenesis QI software. PCMS software was used to sift the quality markers of WXF.RESULTSA total of 25 metabolites were characterized as biomarkers for myocardial ischaemia, and Wenxin Formula reversed the levels of 23 of them that were involved in arachidonic acid metabolism, glycerophospholipid metabolism, lysine degradation, and tyrosine metabolism. Eight constituents absorbed into blood were considered to form the effective material basis of Wenxin Formula for treating myocardial ischaemia, and the Q-markers selected through PCMS were ginsenoside Rb1, cinnamic acid, paeoniflorin and berberine.CONCLUSIONSWXF significantly ameliorated the clinical symptoms, pathological changes and metabolic abnormalities of myocardial ischaemia. This study shows that chinmedomics is a powerful strategy to filter Q-markers from effective constituents to rationally evaluate the efficacy and safety of TCMs.

29 Sep 2022·Evidence-Based Complementary and Alternative Medicine

Effect of WenXin KeLi on Improvement of Arrhythmia after Myocardial Infarction by Intervening PI3K-AKT-mTOR Autophagy Pathway

Article

Author: Wu, Aiming ; Lou, Lixia ; Zhao, Jiuli ; Yang, Ding ; Lv, Meng ; Nie, Bo ; Zhao, Mingjing ; Ji, Xiaodi

Background. Myocardial infarction (MI) is an acute and serious cardiovascular disease. Arrhythmia after MI can lead to sudden cardiac death, which seriously affects the survival outcome of patients. WenXin KeLi is a Chinese patent medicine for the treatment of arrhythmia in a clinic, which can significantly improve symptoms of palpitation and play an important role in reducing the risk of arrhythmia after MI. In this study, we aimed to explore the pharmacological mechanism of WenXin KeLi in protecting the heart. Methods. The MI model was established by ligating the left coronary artery and the ventricular fibrillation threshold (VFT) was measured by electrical stimulation. The expression of connexin43 (CX43) and autophagy-related protein were measured by Western Blot, and correlation analysis was conducted to study the relationship between cardiac autophagy, CX43, and arrhythmia in rats after MI. The effects of WenXin KeLi on arrhythmia, cardiac structure, and function in MI rats were respectively observed by electrical stimulation, cardiac gross section, Masson staining, and cardiac ultrasound. The effects of WenXin KeLi on the expression of phosphoinositide 3 kinase-protein kinase B-mammalian targets of rapamycin (PI3K-AKT-mTOR) autophagy pathway and CX43 were observed by Western Blot. Results. After 4 weeks of MI, the VFT in the model group was significantly reduced, the expression levels of yeast ATG6 homolog (Beclin1), microtubule-associated protein 1A/1B-light chain 3 (LC3II/LC3I), and p-CX43 (S368) significantly increased, the expression of sequestosome-1(P62) and CX43 significantly decreased. LC3II/LC3I and Beclin1 expression were significantly negatively correlated with the VFT, and the expression of P62 and CX43 were significantly positively correlated with the VFT. LC3II/LC3I and Beclin1 expression were negatively correlated with CX43 expression, while P62 expression was positively correlated with CX43 expression. WenXin KeLi could significantly increase the VFT, reduce the deposition of collagen fibers, and increase the index levels of the left ventricular end-diastolic anterior wall (LVEDAW), interventricular septum end-diastolic (IVSED), left ventricular end-systolic anterior wall (LVESAW), interventricular septum end-systolic (IVSES), left ventricular end-diastolic posterior wall (LVEDPW), left ventricular end-systolic posterior wall (LVESPW), left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS), and reduce the index levels of the left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). WenXin KeLi could increase the expression of CX43, P62, AKT, p-PI3K, p-AKT (308), p-AKT (473), and p-mTOR and decrease the expression of LC3II/LC3I and Beclin1. Conclusion. WenXin KeLi can activate the PI3K-AKT-mTOR signaling pathway, improve cardiac autophagy and Cx43 expression in rats after MI, reduce the risk of arrhythmia after MI, and play a cardioprotective role.

100 Deals associated with WenXin

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arrhythmias, Cardiac	CN	Shandong Buchang Pharmaceuticals Co., Ltd.	01 Jan 1995

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

WenXin

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation